Natalie S Ryan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12025565/publications.pdf

Version: 2024-02-01

72	5,771	136950 32	155660 55
papers	citations	h-index	g-index

83	83	83	9602
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Variability in the type and layer distribution of cortical AÎ² pathology in familial Alzheimerâ€™s disease. Brain Pathology, 2022, 32, e13009.	4.1	12
2	AÎ² profiles generated by Alzheimerâ€™s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular Psychiatry, 2022, 27, 2821-2832.	7.9	37
3	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimerâ€™s disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
4	Genetic testing in dementia â€" utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36.	10.1	26
5	The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease. Neurobiology of Aging, 2021, 97, 10-17.	3.1	18
6	Plasma amyloid-Î² ratios in autosomal dominant Alzheimerâ€™s disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	7.6	16
7	A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. Neurobiology of Aging, 2021, 103, 137.e1-137.e5.	3.1	1
8	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. Neuropsychologia, 2021, 162, 108028.	1.6	7
9	Familial Alzheimerâ€™s Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. Cell Reports, 2021, 34, 108615.	6.4	53
10	Familial Alzheimerâ€™s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular Psychiatry, 2020, 25, 2919-2931.	7.9	99
11	Clinical Association of White Matter Hyperintensities Localization in a Mexican Family with Spastic Paraparesis Carrying the PSEN1 A431E Mutation. Journal of Alzheimer's Disease, 2020, 73, 1075-1083.	2.6	6
12	Disease duration in autosomal dominant familial Alzheimer disease. Neurology: Genetics, 2020, 6, e507.	1.9	13
13	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimerâ€™s disease: a retrospective cohort analysis. Alzheimer's Research and Therapy, 2020, 12, 126.	6.2	13
14	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 112.	6.2	18
15	White matter hyperintensity increases are a feature of familial AD and are associated with increased brain atrophy. Alzheimer's and Dementia, 2020, 16, e038925.	0.8	0
16	Disease duration in autosomal dominant familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039738.	0.8	0
17	Premature neuronal differentiation in familial Alzheimerâ€™s disease human stem cells in vitro and in postmortem brain tissue. Alzheimer's and Dementia, 2020, 16, e039793.	0.8	0
18	Plasma phosphoâ€tau in familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.8	0

#	Article	IF	Citations
19	CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease. Neurobiology of Aging, 2020, 91, 5-14.	3.1	30
20	Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout. Brain Communications, 2019, 1, fcz024.	3.3	13
21	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. Brain, 2019, 142, 2082-2095.	7.6	64
22	Extracellular interface between APP and Nicastrin regulates AÎ² length and response to Î³â€secretase modulators. EMBO Journal, 2019, 38, .	7.8	45
23	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 19.	6.2	65
24	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
25	O3â€03â€01: THE SEQUENCE AND TIMING OF PRECLINICAL COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P882.	0.8	1
26	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.8	0
27	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.8	0
28	P1â€524: VISUAL SHORTâ€TERM BINDING DEFICIT IN FAMILIAL ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P532.	0.8	1
29	P3â€461: THE DISTRIBUTION OF CORTICAL AÎ² AND MICROGLIAL PATHOLOGY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1295.	0.8	0
30	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.8	0
31	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.8	423
32	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.1	204
33	Alzheimerâ€™s-Causing Mutations Shift AÎ² Length by Destabilizing Î³-Secretase-AÎ²n Interactions. Cell, 2017, 170, 443-456.e14.	28.9	199
34	[P4â€“261]: LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL AND NEUROIMAGING PROGRESSION IN POSTERIOR CORTICAL ATROPHY. Alzheimer's and Dementia, 2017, 13, P1382.	0.8	0
35	Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease. Brain Research, 2017, 1655, 23-32.	2.2	29
36	[P1â€“219]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. Alzheimer's and Dementia, 2017, 13, P327.	0.8	0

#	Article	IF	Citations
37	[P1â€“220]: 3D CEREBRAL ORGANOIDS AS IN VITRO MODELS FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P327.	0.8	0
38	[P1â€“025]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D. Alzheimer's and Dementia, 2017, 13, P242.	0.8	0
39	[P1â€“180]: DISTINCT AÎ² PRODUCTION IN STEM CELLâ€ÐERIVED CORTICAL NEURONS FROM PATIENTS WITH FAD MUTATION. Alzheimer's and Dementia, 2017, 13, P311.	0.8	0
40	[F4â€“01â€“04]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1211.	0.8	0
41	[O4â€“02â€“04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.8	0
42	O2â€03â€02: are White Matter Hyperintensities a Core Feature of Alzheimerâ€™s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P226.	0.8	1
43	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimerâ€™s Disease. , 2016, 12, P231-P231.		2
44	F5â€02â€02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian. Alzheimer's and Dementia, 2016, 12, P368.	0.8	0
45	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
46	Presymptomatic cortical thinning in familial Alzheimer disease. Neurology, 2016, 87, 2050-2057.	1.1	58
47	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimerâ€™s disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	10.2	163
48	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	5.3	381
49	Diffusion imaging changes in grey matter in Alzheimerâ€™s disease: a potential marker of early neurodegeneration. Alzheimer's Research and Therapy, 2015, 7, 47.	6.2	132
50	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116
51	Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1069-1074.	2.6	22
52	Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy. Brain, 2015, 138, 1976-1991.	7.6	74
53	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	3.1	53
54	Qualitative changes in human Î³-secretase underlie familial Alzheimerâ€™s disease. Journal of Experimental Medicine, 2015, 212, 2003-2013.	8.5	134

#	Article	IF	Citations
55	Alzheimerâ€™s disease in the 100 years since Alzheimerâ€™s death. Brain, 2015, 138, 3816-3821.	7.6	50
56	Imaging endpoints for clinical trials in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 87.	6.2	47
57	Motor features in posterior cortical atrophy and their imaging correlates. Neurobiology of Aging, 2014, 35, 2845-2857.	3.1	29
58	IC-P-193: AUTOMATED SEGMENTATION OF THALAMUS FROM MRI: METHOD VALIDATION AND COMPARISON FOR VOLUMETRIC MEASUREMENT IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P107-P108.		0
59	An unbiased longitudinal analysis framework for tracking white matter changes using diffusion tensor imaging with application to Alzheimer's disease. NeuroImage, 2013, 72, 153-163.	4.2	111
60	Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimerâ€™s disease. Brain, 2013, 136, e259-e259.	7.6	3
61	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.1	67
62	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimerâ€™s disease. Brain, 2013, 136, 1399-1414.	7.6	174
63	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. Journal of Alzheimer's Disease, 2013, 35, 199-212.	2.6	36
64	Cerebral microbleeds in familial Alzheimer's disease. Brain, 2012, 135, e201-e201.	7.6	15
65	Global gray matter changes in posterior cortical atrophy: A serial imaging study. Alzheimer's and Dementia, 2012, 8, 502-512.	0.8	45
66	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiology of Aging, 2012, 33, 627.e1-627.e12.	3.1	74
67	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44
68	The Importance of Group-Wise Registration in Tract Based Spatial Statistics Study of Neurodegeneration: A Simulation Study in Alzheimer's Disease. PLoS ONE, 2012, 7, e45996.	2.5	81
69	Defining and describing the pre-dementia stages of familial Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 29.	6.2	11
70	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain, 2011, 134, 293-300.	7.6	79
71	Correlating familial Alzheimerâ€™s disease gene mutations with clinical phenotype. Biomarkers in Medicine, 2010, 4, 99-112.	1.4	145
72	Imaging Biomarkers in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 20-27.	3.8	9